The X-Rad SmART+ Biological Irradiator for Pre-Clinical Oncology Research

用于临床前肿瘤学研究的 X-Rad SmART 生物辐照器

• 批准号: 10175157
• 负责人: PAT B ZANZONICO
• 金额: $ 60万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-17 至 2022-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10175157
• 关键词: Agreement; Animals; Biological; Biological Response Modifier Therapy; Caliber; Clinical; Clinical Oncology; Collimator; Complex; Computer software; Computers; Dose-Rate; Ensure; External Beam Radiation Therapy; Funding; Investigation; Letters; Manufacturer Name; Memorial Sloan-Kettering Cancer Center; Modality; Modeling; Normal tissue morphology; Patient Care; Performance; Periodicity; Radiation therapy; Request for Applications; Research; Resolution; Resource Sharing; Rodent Model; Roentgen Rays; Rotation; Services; Shapes; Source; System; Therapeutic; Time; Tube; United States National Institutes of Health; Update; Work; base; cancer therapy; cone-beam computed tomography; end of life; experimental study; image guided; imaging system; instrument; irradiation; pre-clinical; programs; research and development; response; treatment planning; tumor

7. Project Summary/Abstract. This application requests funds for a state-of-the-art shared resource, the X-Rad Small-Animal Radiation Therapy (SmART)+ Biological Irradiator (Precision X-Ray, North Branford, CT), to replace our existing X- Rad 225Cx Biological Irradiator (also manufactured by Precision X-Ray). Pursuant to Precision X-Ray’s “end- of-life” letter, “…the EOL (End Of Life) is the date - December 31st, 2020 - after which we will no longer be able to service and/or cover the unit under a new support agreement.” (Precision X-Ray subsequently agreed to provide service support for our X-Rad 225Cx Biological Irradiator exclusive of the X-ray tube and generator through December 31st, 2021.) Radiation therapy (RT) remains, of course, one of the most widely used and effective cancer treatment modalities, and Memorial Sloan Kettering Cancer Center (MSK) has long been recognized as a worldwide leader in research, development, and patient care in RT. Since its installation in 2014, our heavily used X-Rad 225Cx Biological Irradiator has contributed enormously to this legacy, providing invaluable technical capabilities for NIH-funded basic and translational investigations on the response of normal tissues and tumors in experimental rodent models to therapeutic external-beam irradiation. Clinical- grade external-beam radiation therapy is now an essential component of the pre-clinical oncology research program at MSK. The instrument requested, the state-of-the-art X-Rad SmART+, is an image-guided, isocentric (360 rotation, with arc therapy capability), self-shielded research irradiator combining a high- resolution (100 m) cone-beam CT imaging system and a high-dose rate (up to approximately 5 Gy/min) therapeutic X-ray source into a single integrated, computer-controlled platform. It includes a wide variety of fixed-field collimators – circular (0.5 to 25 mm in diameter), square (3 x 3 to 40 x 40 mm), and rectangular (8 x 12 to 30 x 40 mm) – plus an adaptable field-shaping collimator. The X-Rad SmART+ also includes SmART - ATP (Advanced Treatment Planning), a clinical-grade Monte Carlo modeling-based treatment planning system. Similar to its predecessor, the X-Rad 225Cx, the X-Rad SmART+ Biological Irradiator is a complex instrument requiring timely manufacturer-provided service and applications support and periodic software updates to ensure the reliable performance which cutting-edge, often time-sensitive experimental work demands. Without such support, important funded experiments would be very seriously compromised or abandoned altogether. The X-Rad SmART+ Biological Irradiator is thus essential for the ongoing work of numerous highly productive, NIH-funded projects in MSK’s pre-clinical oncology research program.

7. 项目总结/摘要。 该申请要求为最先进的共享资源 X-Rad 小动物辐射提供资金 治疗 (SmART)+ 生物照射器（精密 X 射线，北布兰福德，康涅狄格州），以取代我们现有的 X-射线 Rad 225Cx 生物辐照器（同样由 Precision X-Ray 制造），符合 Precision X-Ray 的“最终标准”。 of-life”信函，“……EOL（生命周期结束）是日期 - 2020 年 12 月 31 日 - 在此之后我们将不再能够 根据新的支持协议为该设备提供服务和/或覆盖。”（Precision X-Ray 随后同意 为我们的 X-Rad 225Cx 生物辐照器（不包括 X 射线管和发生器）提供服务支持 到 2021 年 12 月 31 日。）当然，放射治疗 (RT) 仍然是最广泛使用和最有效的治疗方法之一。 有效的癌症治疗方式，纪念斯隆凯特琳癌症中心 (MSK) 长期以来一直致力于 自安装以来，被公认为 RT 研究、开发和患者护理领域的全球领导者。 2014 年，我们大量使用的 X-Rad 225Cx 生物辐照器为这一传统做出了巨大贡献，提供 NIH 资助的基础和转化研究的宝贵技术能力 实验啮齿动物模型中的正常组织和肿瘤进行临床治疗。 级外束放射治疗现已成为临床前肿瘤学研究的重要组成部分 MSK 的计划所要求的仪器是最先进的 X-Rad SmART+，是一种图像引导的、 等中心（360°旋转，具有电弧治疗能力），自屏蔽研究辐照器结合了高 分辨率 (100 µm) 锥束 CT 成像系统和高剂量率（高达约 5 Gy/min） 它包括多种治疗 X 射线源到一个集成的计算机控制平台中。 固定场准直器 – 圆形（直径 0.5 至 25 毫米）、方形（3 x 3 至 40 x 40 毫米）和矩形（8 x 12 至 30 x 40 mm) – 加上一个适应性强的场整形准直器 X-Rad SmART+ 还包括 SmART -。 ATP（高级治疗计划），一种基于蒙特卡罗建模的临床级治疗计划系统。 与其前身 X-Rad 225Cx 类似，X-Rad SmART+ 生物辐照仪是一款复杂的仪器 需要制造商及时提供服务和应用程序支持以及定期软件更新 确保尖端、时间敏感的实验工作所需的可靠性能。 如果没有这种支持，重要的资助实验将受到严重损害或完全放弃。 因此，X-Rad SmART+ 生物辐照器对于众多高产、高效的持续工作至关重要。 NIH 资助了 MSK 斯隆临床前肿瘤学研究项目。